Recruiting
Phase 2

MM402

Sponsor:

Definium Therapeutics US, Inc.

Code:

NCT07303907

Conditions

Autism Spectrum Disorder

ASD

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-26. This information was provided to ClinicalTrials.gov by Definium Therapeutics US, Inc. on 2026-04-06.